A Phase III, Open Label, Randomized Study of AZD9291 Versus Platinum-Based Doublet Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene (AURA3)

Trial Profile

A Phase III, Open Label, Randomized Study of AZD9291 Versus Platinum-Based Doublet Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene (AURA3)

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Osimertinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AURA3
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 Oct 2017 Results assessing concordance between plasma circulating tumor DNA (ctDNA) and tissue for the detection of EGFR mutations using three distinct plasma detection technologies in the Osimertinib Phase III Trial, presented at the 18th World Conference on Lung Cancer.
    • 23 Jun 2017 Planned End Date changed from 1 Jan 2018 to 31 Aug 2018.
    • 06 Jun 2017 Results of population pharmacokinetic and pharmacodynamic analysis using data from three AURA studies (AURA, AURA 2 and AURA 3) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top